Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut SyndromeAug 30, 2021 | News
Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet SyndromeAug 2, 2021 | News
Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet SyndromeAug 2, 2021 | News
Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut SyndromeAug 2, 2021 | NewsRead Full Press Release: https://www.prnewswire.com/news-releases/epygenix-therapeutics-receives-us-fda-orphan-drug-designation-for-epx-200-in-lennox-gastaut-syndrome-301345811.html
Epygenix: Fishing for best in class in epilepsyMay 25, 2021 | NewsRead Full Press Release Here: https://www.biocentury.com/article/636563/epygenix-fishing-for-best-in-class-in-epilepsy
Journey from Aquarium-to-Bedside to Treat Genetic EpilepsiesMay 3, 2021 | NewsRead Full Press Release Here: https://www.fiercepharma.com/sponsored/journey-from-aquarium-to-bedside-to-treat-genetic-epilepsies
